173 related articles for article (PubMed ID: 21080647)
1. Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor.
Moffat D; Patel S; Day F; Belfield A; Donald A; Rowlands M; Wibawa J; Brotherton D; Stimson L; Clark V; Owen J; Bawden L; Box G; Bone E; Mortenson P; Hardcastle A; van Meurs S; Eccles S; Raynaud F; Aherne W
J Med Chem; 2010 Dec; 53(24):8663-78. PubMed ID: 21080647
[TBL] [Abstract][Full Text] [Related]
2. Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.
Wang H; Yu N; Chen D; Lee KC; Lye PL; Chang JW; Deng W; Ng MC; Lu T; Khoo ML; Poulsen A; Sangthongpitag K; Wu X; Hu C; Goh KC; Wang X; Fang L; Goh KL; Khng HH; Goh SK; Yeo P; Liu X; Bonday Z; Wood JM; Dymock BW; Kantharaj E; Sun ET
J Med Chem; 2011 Jul; 54(13):4694-720. PubMed ID: 21634430
[TBL] [Abstract][Full Text] [Related]
3. Optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90. Identification of development candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide.
Zehnder L; Bennett M; Meng J; Huang B; Ninkovic S; Wang F; Braganza J; Tatlock J; Jewell T; Zhou JZ; Burke B; Wang J; Maegley K; Mehta PP; Yin MJ; Gajiwala KS; Hickey MJ; Yamazaki S; Smith E; Kang P; Sistla A; Dovalsantos E; Gehring MR; Kania R; Wythes M; Kung PP
J Med Chem; 2011 May; 54(9):3368-85. PubMed ID: 21438541
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.
Wong JC; Tang G; Wu X; Liang C; Zhang Z; Guo L; Peng Z; Zhang W; Lin X; Wang Z; Mei J; Chen J; Pan S; Zhang N; Liu Y; Zhou M; Feng L; Zhao W; Li S; Zhang C; Zhang M; Rong Y; Jin TG; Zhang X; Ren S; Ji Y; Zhao R; She J; Ren Y; Xu C; Chen D; Cai J; Shan S; Pan D; Ning Z; Lu X; Chen T; He Y; Chen L
J Med Chem; 2012 Oct; 55(20):8903-25. PubMed ID: 23061376
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitor.
Cee VJ; Schenkel LB; Hodous BL; Deak HL; Nguyen HN; Olivieri PR; Romero K; Bak A; Be X; Bellon S; Bush TL; Cheng AC; Chung G; Coats S; Eden PM; Hanestad K; Gallant PL; Gu Y; Huang X; Kendall RL; Lin MH; Morrison MJ; Patel VF; Radinsky R; Rose PE; Ross S; Sun JR; Tang J; Zhao H; Payton M; Geuns-Meyer SD
J Med Chem; 2010 Sep; 53(17):6368-77. PubMed ID: 20684549
[TBL] [Abstract][Full Text] [Related]
6. Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.
Angibaud P; Van Emelen K; Decrane L; van Brandt S; Ten Holte P; Pilatte I; Roux B; Poncelet V; Speybrouck D; Queguiner L; Gaurrand S; Mariën A; Floren W; Janssen L; Verdonck M; van Dun J; van Gompel J; Gilissen R; Mackie C; Du Jardin M; Peeters J; Noppe M; Van Hijfte L; Freyne E; Page M; Janicot M; Arts J
Bioorg Med Chem Lett; 2010 Jan; 20(1):294-8. PubMed ID: 19906529
[TBL] [Abstract][Full Text] [Related]
7. Potent, selective, and orally bioavailable inhibitors of mammalian target of rapamycin (mTOR) kinase based on a quaternary substituted dihydrofuropyrimidine.
Cohen F; Bergeron P; Blackwood E; Bowman KK; Chen H; Dipasquale AG; Epler JA; Koehler MF; Lau K; Lewis C; Liu L; Ly CQ; Malek S; Nonomiya J; Ortwine DF; Pei Z; Robarge KD; Sideris S; Trinh L; Truong T; Wu J; Zhao X; Lyssikatos JP
J Med Chem; 2011 May; 54(9):3426-35. PubMed ID: 21495671
[TBL] [Abstract][Full Text] [Related]
8. N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824).
Remiszewski SW; Sambucetti LC; Bair KW; Bontempo J; Cesarz D; Chandramouli N; Chen R; Cheung M; Cornell-Kennon S; Dean K; Diamantidis G; France D; Green MA; Howell KL; Kashi R; Kwon P; Lassota P; Martin MS; Mou Y; Perez LB; Sharma S; Smith T; Sorensen E; Taplin F; Trogani N; Versace R; Walker H; Weltchek-Engler S; Wood A; Wu A; Atadja P
J Med Chem; 2003 Oct; 46(21):4609-24. PubMed ID: 14521422
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological characterization of amidopropenyl hydroxamates as HDAC inhibitors.
Thaler F; Varasi M; Colombo A; Boggio R; Munari D; Regalia N; Rozio MG; Reali V; Resconi AE; Mai A; Gagliardi S; Dondio G; Minucci S; Mercurio C
ChemMedChem; 2010 Aug; 5(8):1359-72. PubMed ID: 20572281
[TBL] [Abstract][Full Text] [Related]
10. Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor.
Brasca MG; Amboldi N; Ballinari D; Cameron A; Casale E; Cervi G; Colombo M; Colotta F; Croci V; D'Alessio R; Fiorentini F; Isacchi A; Mercurio C; Moretti W; Panzeri A; Pastori W; Pevarello P; Quartieri F; Roletto F; Traquandi G; Vianello P; Vulpetti A; Ciomei M
J Med Chem; 2009 Aug; 52(16):5152-63. PubMed ID: 19603809
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and antitumor effect in vitro and in vivo of substituted 1,3-dihydroindole-2-ones.
Christensen MK; Erichsen KD; Trojel-Hansen C; Tjørnelund J; Nielsen SJ; Frydenvang K; Johansen TN; Nielsen B; Sehested M; Jensen PB; Ikaunieks M; Zaichenko A; Loza E; Kalvinsh I; Björkling F
J Med Chem; 2010 Oct; 53(19):7140-5. PubMed ID: 20845961
[TBL] [Abstract][Full Text] [Related]
12. SAR and biological evaluation of analogues of a small molecule histone deacetylase inhibitor N-(2-aminophenyl)-4-((4-(pyridin-3-yl)pyrimidin-2-ylamino)methyl)benzamide (MGCD0103).
Raeppel S; Zhou N; Gaudette F; Leit S; Paquin I; Larouche G; Moradei O; Fréchette S; Isakovic L; Delorme D; Fournel M; Kalita A; Lu A; Trachy-Bourget MC; Yan PT; Liu J; Rahil J; Wang J; Besterman JM; Murakami K; Li Z; Vaisburg A
Bioorg Med Chem Lett; 2009 Feb; 19(3):644-9. PubMed ID: 19114304
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and bioevalution of novel benzamides derivatives as HDAC inhibitors.
Li Y; Zhou Y; Qian P; Wang Y; Jiang F; Yao Z; Hu W; Zhao Y; Li S
Bioorg Med Chem Lett; 2013 Jan; 23(1):179-82. PubMed ID: 23206867
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.
Kinzel O; Llauger-Bufi L; Pescatore G; Rowley M; Schultz-Fademrecht C; Monteagudo E; Fonsi M; Gonzalez Paz O; Fiore F; Steinkühler C; Jones P
J Med Chem; 2009 Jun; 52(11):3453-6. PubMed ID: 19441846
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and anticancer activity of piperazine hydroxamates and their histone deacetylase (HDAC) inhibitory activity.
Chetan B; Bunha M; Jagrat M; Sinha BN; Saiko P; Graser G; Szekeres T; Raman G; Rajendran P; Moorthy D; Basu A; Jayaprakash V
Bioorg Med Chem Lett; 2010 Jul; 20(13):3906-10. PubMed ID: 20605448
[TBL] [Abstract][Full Text] [Related]
16. N-Hydroxy-1,2-disubstituted-1H-benzimidazol-5-yl acrylamides as novel histone deacetylase inhibitors: design, synthesis, SAR studies, and in vivo antitumor activity.
Wang H; Yu N; Song H; Chen D; Zou Y; Deng W; Lye PL; Chang J; Ng M; Sun ET; Sangthongpitag K; Wang X; Wu X; Khng HH; Fang L; Goh SK; Ong WC; Bonday Z; Stünkel W; Poulsen A; Entzeroth M
Bioorg Med Chem Lett; 2009 Mar; 19(5):1403-8. PubMed ID: 19181524
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors.
Itoh Y; Suzuki T; Kouketsu A; Suzuki N; Maeda S; Yoshida M; Nakagawa H; Miyata N
J Med Chem; 2007 Nov; 50(22):5425-38. PubMed ID: 17929798
[TBL] [Abstract][Full Text] [Related]
18. YM753, a novel histone deacetylase inhibitor, exhibits antitumor activity with selective, sustained accumulation of acetylated histones in tumors in the WiDr xenograft model.
Shindoh N; Mori M; Terada Y; Oda K; Amino N; Kita A; Taniguchi M; Sohda KY; Nagai K; Sowa Y; Masuoka Y; Orita M; Sasamata M; Matsushime H; Furuichi K; Sakai T
Int J Oncol; 2008 Mar; 32(3):545-55. PubMed ID: 18292931
[TBL] [Abstract][Full Text] [Related]
19. New aryldithiolethione derivatives as potent histone deacetylase inhibitors.
Tazzari V; Cappelletti G; Casagrande M; Perrino E; Renzi L; Del Soldato P; Sparatore A
Bioorg Med Chem; 2010 Jun; 18(12):4187-94. PubMed ID: 20576572
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of N-hydroxyphenylacrylamides and N-hydroxypyridin-2-ylacrylamides as novel histone deacetylase inhibitors.
Thaler F; Colombo A; Mai A; Amici R; Bigogno C; Boggio R; Cappa A; Carrara S; Cataudella T; Fusar F; Gianti E; di Ventimiglia SJ; Moroni M; Munari D; Pain G; Regalia N; Sartori L; Vultaggio S; Dondio G; Gagliardi S; Minucci S; Mercurio C; Varasi M
J Med Chem; 2010 Jan; 53(2):822-39. PubMed ID: 20017493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
